Abstract
Acetylcysteine (ACC) helps people with pulmonary fibrosis and it is preferred treatment for the often deadly adult respiratory distress syndrome. ACC is a precursor in the formation of the glutathione antioxidant in the body. Compounds of zinc (II) and iron (II) with ACC and mucolytic medications play an important role in medical practice for the prevention of respiratory diseases. The present article is about determining the embryotoxicity of the new coordination compounds of Zincas and Feras, which are synthesized by the interaction of zinc (II) and iron (II) sulfates with acetylcysteine in an aqueous solution and have mucolytic properties in relation to diseases, bronchial asthma with a predominance of an infectious-dependent component of the course, chronic asthmatic bronchitis and chronic obstructive bronchitis. Daily administration of a feed or a high dose of 0.60 ml / kg inside the gastric suspension for 3 weeks to pregnant rats and the result of observation of the 13th week of life did not have a marked effect on the fetal development process. With the introduction of Feras and Zincas in a therapeutic dose for 1-3 weeks of pregnancy, the death of rat pups in the first month of life was comparable with the control values. The physical development of the offspring proceeded without any deviations from the norm. All pups were born normal, responded to external irritants well, with а good appetite and led an active lifestyle.
Highlights
In recent years, the need to create medications with lower toxicity and high activity and to improve the scope of medicinal substances has increased
The purpose of the investigation was to study the toxic properties of the synthesized coordination compound of zinc (II) and iron (II) with acetylcysteine, the possibility of teratogenic and embryotoxic effects of Zincas and Feras fed in white rats, and the search for new, more effective mucolytic agents
The chemical name of Feras and Zincas according to the nomenclature of UPAC coordination compounds is iron (II) diacetylcysteinate and zinc (II) diacetylcysteinate
Summary
The need to create medications with lower toxicity and high activity and to improve the scope of medicinal substances has increased. First of all, the ratio of benefits and harms from taking certain medications is assessed and they are prescribed only if the probability of a therapeutic effect for the mother outweighs the risk of the development of an undesirable effect on the fetus Only those medicines are prescribed that are already experienced in their widespread use during pregnancy. The purpose of the investigation was to study the toxic properties of the synthesized coordination compound of zinc (II) and iron (II) with acetylcysteine, the possibility of teratogenic and embryotoxic effects of Zincas and Feras fed in white rats, and the search for new, more effective mucolytic agents. The chemical name of Feras and Zincas according to the nomenclature of UPAC coordination compounds is iron (II) diacetylcysteinate and zinc (II) diacetylcysteinate
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
